Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.70 |
| ▸ | CD69 | Q07108 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | BMX | P51813 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067184 | 0.96 | BTK (0.69) | BTKCD69 | |
| SCHEMBL13305710 | 0.95 | BTK (0.70) | BTKCD69EGFRBMXJAK3 | |
| SCHEMBL13305714 | 0.94 | BTK (0.69) | BTKCD69EGFRBMXJAK3 | |
| SCHEMBL1069297 | 0.94 | BTK (0.69) | BTKCD69EGFRBMXJAK3 | |
| SCHEMBL1069778 | 0.93 | BTK (0.68) | BTKCD69 | |
| SCHEMBL13305716 | 0.93 | BTK (0.69) | BTKCD69EGFRBMXJAK3 | |
| SCHEMBL16712285 | 0.92 | BTK (0.68) | BTKCD69 | |
| SCHEMBL1071010 | 0.92 | BTK (0.82) | BTKCD69EGFRBMXJAK3 | |
| SCHEMBL13305717 | 0.91 | BTK (0.68) | BTKCD69EGFRBMXJAK3 | |
| SCHEMBL1068534 | 0.91 | BTK (0.69) | BTKCD69EGFRBMXJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2270200-A2 | Kinase inhibitors, and methods of using and identifying kinase inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | BTK, LYN, LCK | BTK 1/4885CD69 1026/4885EGFR 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.